Interestingly, substantial increases in immune checkpoint therapy targets such as PD-L1 + tumor cells, PD-L1 + Tregs, and CTLA-4 + Tregs (Fig. 10c–e) were found. The gene discussed is CTLA4; the disease is neoplasm.